Armodafinil, drug used to treat daytime sleepiness does not appear to improve driving in those with sleep apnea, revealed researchers. Nor did those taking the drug report less daytime sleepiness than those receiving a placebo, as measured by the Epworth Sleepiness Scale and the Functional Outcomes of Sleep Questionnaire.
Drowsy Driving
Drowsy driving means operating a motor vehicle when a person is unable to remain alert due to lack of sleep. It is a major cause of motor vehicle accidents and can affect the human brain as much as alcohol. Avoid driving if you feel drowsy or exhausted
Advertisement
‘Armodafinil, commonly used to treat daytime sleepiness did not improve the driving performance of those with obstructive sleep apnea after six months of use.’
Tweet it Now
In the study, 113 participants (ages 18 to 70) were randomly assigned to either receive 150 mg of armodafinil daily or a placebo. Participants had moderate to severe OSA, were moderately obese and did not use continuous positive airway pressure (CPAP) or an oral appliance that advances their lower jaw. Both therapies treat OSA by preventing the pauses in breathing that occur in OSA when the back of the throat collapses. All participants were also randomly assigned to one of two popular diets in Australia: the Australian Guide to Healthy Eating diet, which is similar to the American Dietary Guidelines "Choose My Plate," or a low-glycemic index, high-protein diet. Driving ability was assessed during a simulated 90-minute drive. According to Dr. Marshall, a clinical trials epidemiologist, about half of patients seen in sleep clinics fall into the category of having sleep apnea and abdominal obesity but being unable to tolerate CPAP or an oral appliance. "My clinical colleagues and I call these patients the 'forgotten patients,'" he said. "We felt we needed to help our patients lose weight to address their metabolic risks over the longer term whilst addressing their sleepiness and neurocognitive dysfunction immediately with armodafinil."
He added that sporadic reports indicate that patients using armodafinil and its cousin modafinil to improve wakefulness experienced weight loss, so he and his coauthors wanted to test whether the drugs might increase the success of a deliberate weight loss program.
In the current study, armodafinil did, in fact, have a positive effect on body mass. Participants on the drug lost more body fat on either of the diets, which appeared to reduce weight equally well, than those who received the placebo. At six months, those in the armodafinil arm of the study lost an average of 6.4 pounds more body fat than those receiving the placebo. The researchers said that some of this additional weight loss may be due to the increased activity levels of those receiving the drug, as measured by an activity tracker. Importantly, the authors noted that armodafinil did not appear to increase blood pressure.
![Armodafinil]( "Armodafinil")
This medication is a stimulant, prescribed for excessive sleepiness caused by obstructive sleep apnea, narcolepsy (a condition that causes excessive daytime sleepiness) or shift work sleep disorder.
Armodafinil also appeared to improve driving ability after three months. The researchers speculate that those taking armodafinil learned their simulated driving tasks faster than those receiving the placebo because by six months there was no difference between the two groups. Even with the improvements that came with practice, the authors noted that, on average, driving ability among these participants with untreated OSA was two standard deviations worse than healthy people without OSA.
Source: Eurekalert
Armodafinil
This medication is a stimulant, prescribed for excessive sleepiness caused by obstructive sleep apnea, narcolepsy (a condition that causes excessive daytime sleepiness) or shift work sleep disorder.
Advertisement
Armodafinil also appeared to improve driving ability after three months. The researchers speculate that those taking armodafinil learned their simulated driving tasks faster than those receiving the placebo because by six months there was no difference between the two groups. Even with the improvements that came with practice, the authors noted that, on average, driving ability among these participants with untreated OSA was two standard deviations worse than healthy people without OSA.
Source: Eurekalert
Alcohol and Driving
Alcohol and driving do not mix. Drunken driving is the cause of many deaths in the world.
Advertisement
 Sleeping DisordersHow many times have you stayed awake in the dead of the night counting sheep? If it is fairly often then you could be suffering from a sleep disorder! | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.